AstraZeneca scores with Imfinzi in another bladder cancer trial, rivaling…
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA approval…
Fonte
fiercepharma.com
8articoli totali nell'archivio
Biopharma leaders rally behind Pazdur for FDA commissioner pick. But does he…
With the FDA now rudderless following the revelation that commissioner Marty Makary, M.D., is stepping down, voices across…
Regulatory tracker: Taiho's Inqovi widens its reach with FDA label expansion
Welcome to Fierce Pharma's regulatory tracker for the first half of 2026. | In this tracker, Fierce Pharma is recording the…
FDA floats possible approach to repurpose approved drugs under new uses
The FDA is looking to get thrifty with its approved drugs. | The framework would leverage existing safety data on approved drugs…
As Trump arrives in China, Big Pharma CEOs are notably absent
As President Donald Trump lands in Beijing, one major industry is missing from his business delegation—pharma. | As President…
Targeted Protein Degradation and Novel Modalities: Getting on the Frontline
Targeted protein degradation is changing how drug discovery teams think about disease biology. For many years, small molecule…
Integrated CDO capabilities reduce early development complexity
Strengthening core CDO values for cell line development | Strengthening core CDO values for cell line development